This Experimental Hematology & Oncology series on 'New developments in CAR T, CAR NK, and CAR macrophage cell therapies' is open. CAR engineered cell therapies are moving rapidly from bench to bedside. This collection welcomes studies covering the latest development in pre-clinical and clinical studies of CAR -engineered cell therapies. Submissions can be made via the journal's submission system. For more information, visit the full collection webpage.
Call for papers: New developments in CAR T, CAR NK, and CAR macrophage cell therapies
Call for papers: Latest updates from major conferences
This Experimental Hematology & Oncology and Journal of Hematology & Oncology series intends to publish Correspondences with latest updates on novel agents and regimens from major conferences on blood and cancer disorders. Each Correspondence serves as a summary and analysis of 5 or more abstracts on a similar focus from a major international conference. Submissions can be made via the journal's submission system. For more information, visit the full collection page.
Featured Article: The emerging scenario of immunotherapy for T-cell Acute Lymphoblastic Leukemia: advances, challenges and future perspectives
In a new review, Caracciolo et al. look over new developments, challenges and perspectives of the emerging landscape of immunotherapy of T-cell malignancies.
Cancer Awareness Month Collections
Aims and scope
Experimental Hematology & Oncology is an open access journal that encompasses all aspects of hematology and oncology with an emphasis on preclinical, basic, patient-oriented and translational research. The journal acts as an international platform for sharing laboratory findings in these areas and makes a deliberate effort to publish clinical trials with 'negative' results and basic science studies with provocative findings.
Delong Liu, New York Medical College
Kongming Wu, Tongji Medical College
Editor's quote (Dr. Delong Liu)
"Like our companion journal, Journal of Hematology & Oncology, Experimental Hematology & Oncology publishes on all aspects of hematology and oncology, which are closely intertwined and rapidly evolving fields. It also emphasizes basic and translational research, as well as patient-oriented research and clinical trials with ‘negative’ or preliminary results. The journal is an international platform for sharing findings in these areas and adheres to fast turnaround times."
Annual Journal Metrics
2022 Citation Impact
11.4 - 2-year Impact Factor
7.3 - 5-year Impact Factor
1.609 - SNIP (Source Normalized Impact per Paper)
1.908 - SJR (SCImago Journal Rank)
3 days submission to first editorial decision for all manuscripts (Median)
79 days submission to accept (Median)
840 Altmetric mentions
On the blog
06 April 2023